FDA reviews continue for now

Share this article:

Banked user fees are keeping the FDA review process humming for now, reports MedPage Today, which notes that the agency approved the prescription hot flashes medication Duavee Thursday and plans to hold its advisory committee meeting for Medtronic devices this week. This in addition to green-lighting an IV nutritional treatment called Clinolipid on Thursday.

The omega-three/omega-six fatty acid blend was granted priority review to alleviate a drug shortage. MedPage Today notes that although user fees fund the regulator's review processes, they only cover around two-thirds of the cost, putting future reviews in limbo under the shutdown. As noted last week, more than half of the non-furloughed FDA employees are funded by user fees, but only 55% of the agency's staff is allowed to work until the shutdown is resolved.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.